Investor Overview

Corporate Profile
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Company’s NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Company’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Company’s NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Company’s third-party licensees.
RGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$12.44
Change (%) Stock is Down 0.08 (0.64%)
Volume144,497
Data as of 08/26/16 4:00 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: RGNX.O.  Currently trading at $12.44 with a 52 week high of $32.00 and a 52 week low of $7.07.
Recent NewsMore >>
DateTitle 
08/16/16Daniel Tassé Appointed to REGENXBIO Board of Directors
ROCKVILLE, Md., Aug. 16, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced the appointment of Daniel Tassé to its board of directors, effective August 15, 2016. "On behalf of the board of directors, I am pleased to welcome Daniel to REGENXBIO. Daniel’s extensive global execut... 
Printer Friendly Version
08/09/16REGENXBIO Reports Second Quarter 2016 Financial Results and Recent Operational Highlights
On track to enroll first patients for Phase I/II clinical trial of RGX-501 for the treatment of homozygous familial hypercholesterolemia in the second half of 2016 Received FDA Rare Pediatric Disease Designation for RGX-121 for the treatment of Mucopolysaccharidosis Type II Entered into an exclusive license agreement with Biogen for the development of gene therapies for rare genetic vision disorders $198.7 million in cash, cash equivalents and marketable securities as of June 30, 2016 ... 
Printer Friendly Version
08/08/16Daniel J. Abdun-Nabi Appointed to REGENXBIO Board of Directors
ROCKVILLE, Md., Aug. 08, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced the appointment of Daniel J. Abdun-Nabi to its board of directors, effective as of August 5, 2016. "Dan is an experienced biopharmaceutical leader who brings to REGENXBIO more than 25 years of succes... 
Printer Friendly Version
08/02/16FDA Grants Rare Pediatric Disease Designation to REGENXBIO's RGX-121 Gene Therapy for the Treatment of Mucopolysaccharidosis Type II (MPS II)
ROCKVILLE, Md., Aug. 02, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to RGX-121, REGENXBIO’s investigational gene therapy product candidate for the treatment of Mucopolysaccha... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever REGENXBIO posts new information to the site. Just enter your e-mail address and click Submit.